8189 — Tianjin TEDA Biomedical Engineering Co Income Statement
0.000.00%
- HK$153.50m
- HK$252.74m
- CNY398.00m
Annual income statement for Tianjin TEDA Biomedical Engineering Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | R2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 359 | 369 | 476 | 404 | 398 |
Cost of Revenue | |||||
Gross Profit | 35 | 40.4 | 45.6 | 14.8 | 21.4 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 418 | 392 | 501 | 416 | 394 |
Operating Profit | -58.8 | -22.9 | -24.8 | -12.5 | 4.34 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -88.8 | -50 | -44.8 | -24.1 | -12 |
Provision for Income Taxes | |||||
Net Income After Taxes | -88.8 | -50.4 | -44.8 | -23.5 | -11 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | -84.6 | -48 | -42.3 | -27.5 | -20.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -84.6 | -48 | -42.3 | -27.5 | -20.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.034 | -0.022 | -0.015 | -0.015 | -0.013 |